Sartorius Enhances AI Capabilities in Drug Discovery and Manufacturing with NVIDIA Collaboration

Sartorius AG, a prominent life science group, announced the expansion of its collaboration with NVIDIA to accelerate the development and manufacturing of pharmaceutical drugs using artificial intelligence (AI). The partnership, initially started in 2020, focuses on integrating NVIDIA's advanced computing platforms and AI solutions into Sartorius’ life science applications.

According to Prof. Dr. Oscar-Werner Reif, Sartorius' Chief Technology Officer, this collaboration aims to harness AI for improving data utilization in biopharma drug discovery and manufacturing processes. Notably, Sartorius plans to employ NVIDIA’s technologies in live-cell imaging and the predictive design of manufacturing processes, which could lead to significant advancements in creating novel therapies more efficiently.

The joint effort will also include the adoption of the NVIDIA Clara AI platform, enhancing the capabilities within the Sartorius ecosystem to include new predictive AI models, tools, and simulations. This initiative is poised to impact various stages of pharmaceutical development by enabling the creation of more sophisticated models, including 3D-bioprinted organoids and synthetic biological pathways.

This strategic partnership marks a notable progression in the integration of AI technology in the life sciences sector, portraying a forward-looking approach to meeting the complex demands of modern biopharmaceutical research and production.